"The voice for cancer physicians and their patients in Massachusetts."

Kadmon, a Sanofi company, received approval for REZUROCK™ (belumosudil) tablets, for oral use

23 Dec 2021 12:00 PM | Katy Monaco (Administrator)

REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.  Prescribing Information.  Visit Kadmon at https://kadmon.com/.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software